Pentadeca Arginate — EU research guide.
Pentadeca Arginate (PDA) is the arginate-salt form of BPC-157 — the same 15–amino-acid sequence bound to arginine instead of acetate. The modification is claimed to improve stability and shelf life while retaining BPC-157's tissue-repair profile.
- Same 15-amino-acid sequence as BPC-157, prepared as an arginate (not acetate) salt.
- The arginate salt is claimed to improve stability and shelf life; the active peptide is unchanged.
- No independent human clinical trials of PDA specifically — evidence is the BPC-157 animal literature.
- Claims of superiority over standard BPC-157 rest on the stability argument, not comparative data.
- Not approved by any regulator; sold as a research compound only.
What is Pentadeca Arginate?
Pentadeca Arginate (PDA) is not a new molecule in the strict sense — it is BPC-157 (a 15-amino-acid "Body Protection Compound" fragment originally identified in gastric juice) prepared as an arginate salt rather than the more common acetate salt. "Pentadeca" refers to the fifteen residues; "arginate" refers to the arginine counter-ion. The active peptide sequence is identical to BPC-157; what changes is the salt form, which vendors claim improves stability in acidic conditions and shelf life.
How is it different from BPC-157?
Functionally, PDA and BPC-157 share the same proposed mechanisms: promotion of angiogenesis (new blood-vessel formation), modulation of the nitric-oxide system, collagen synthesis support, and anti-inflammatory signalling without fully suppressing the repair response. The main practical difference is the counter-ion. Some vendors market the arginine component as providing additional nitric-oxide benefit, but at the molar quantities present in a typical microgram-scale peptide dose, the independent arginine contribution is pharmacologically minor. The realistic distinction is salt stability, not a different drug.
What does the research show?
There are no large human clinical trials of PDA specifically. The evidence base is the BPC-157 literature — predominantly rodent studies showing accelerated tendon-to-bone healing, ligament and muscle repair, and gastrointestinal protection — plus anecdotal community reports. PDA inherits this evidence by virtue of being the same peptide; it does not have an independent human trial record of its own as of mid-2026. Claims of superiority over standard BPC-157 rest on the stability argument, not on comparative clinical data.
EU legal status
Not approved as a medicine in the EU. PDA occupies the same unscheduled "research chemical" position as BPC-157 — not specifically prohibited by name in most member states, but not legal for human use, sale as a medicine, or marketing with therapeutic claims. It is sold by research-peptide vendors as a laboratory compound.
Molecular information
Pharmacokinetics
Pentadeca Arginate across EU suppliers
COA-verified EU vendors · Updated monthly